Advertisement
Screener

TELA Bio, Inc. (TELA) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

TELA Bio, Inc. Research and Development Expense

TELA Bio, Inc. (TELA) reported Research and Development Expense of $2.72 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11

  • TELA Bio, Inc. research and development expense for the quarter ending 2026-06-30 was $2.72M, a 23.60% increase year-over-year.
  • TELA Bio, Inc. research and development expense for the quarter ending 2026-03-31 was $2.34M, a 7.76% decline year-over-year.
  • TELA Bio, Inc. research and development expense for the quarter ending 2025-12-31 was $2.13M, a 4.93% increase year-over-year.
  • TELA Bio, Inc. research and development expense for the quarter ending 2025-09-30 was $2.35M, a 13.54% increase year-over-year.
  • TELA Bio, Inc. research and development expense for fiscal 2025 was $9.22M, a 4.62% increase from fiscal 2024.
  • TELA Bio, Inc. research and development expense for fiscal 2024 was $8.81M, a 8.38% decline from fiscal 2023.
  • TELA Bio, Inc. research and development expense for fiscal 2023 was $9.62M, a 7.63% increase from fiscal 2022.
  • TELA Bio, Inc. research and development expense for fiscal 2022 was $8.94M, a 32.54% increase from fiscal 2021.
Period endResearch and Development Expense 3 monthResearch and Development Expense 6 monthResearch and Development Expense 9 monthResearch and Development Expense 12 month
2026-06-30$2.72M
10-Q · filed 2026-08-11
$5.07M
10-Q · filed 2026-08-11
$7.20M
derived: sum of 3 quarters · filed 2026-08-11
$9.54M
derived: sum of 4 quarters · filed 2026-08-11
2026-03-31$2.34M
10-Q · filed 2026-05-13
$4.47M
derived: sum of 2 quarters · filed 2026-05-13
$6.82M
derived: sum of 3 quarters · filed 2026-05-13
$9.02M
derived: sum of 4 quarters · filed 2026-08-11
2025-12-31$2.13M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
$4.48M
derived: sum of 2 quarters · filed 2026-03-25
$6.68M
derived: sum of 3 quarters · filed 2026-08-11
$9.22M
10-K · filed 2026-03-25
2025-09-30$2.35M
10-Q · filed 2025-11-14
$4.55M
derived: sum of 2 quarters · filed 2026-08-11
$7.09M
10-Q · filed 2025-11-14
$9.12M
derived: sum of 4 quarters · filed 2026-08-11
2025-06-30$2.20M
10-Q · filed 2026-08-11
$4.74M
10-Q · filed 2026-08-11
$6.77M
derived: sum of 3 quarters · filed 2026-08-11
$8.84M
derived: sum of 4 quarters · filed 2026-08-11
2025-03-31$2.54M
10-Q · filed 2026-05-13
$4.57M
derived: sum of 2 quarters · filed 2026-05-13
$6.64M
derived: sum of 3 quarters · filed 2026-05-13
$8.96M
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31$2.03M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
$4.10M
derived: sum of 2 quarters · filed 2026-03-25
$6.42M
derived: sum of 3 quarters · filed 2026-03-25
$8.81M
10-K · filed 2026-03-25
2024-09-30$2.07M
10-Q · filed 2025-11-14
$4.39M
derived: sum of 2 quarters · filed 2025-11-14
$6.78M
10-Q · filed 2025-11-14
$9.47M
derived: sum of 4 quarters · filed 2026-03-25
2024-06-30$2.32M
10-Q · filed 2025-08-11
$4.72M
10-Q · filed 2025-08-11
$7.40M
derived: sum of 3 quarters · filed 2026-03-25
$9.77M
derived: sum of 4 quarters · filed 2026-03-25
2024-03-31$2.39M
10-Q · filed 2025-05-08
$5.08M
derived: sum of 2 quarters · filed 2026-03-25
$7.45M
derived: sum of 3 quarters · filed 2026-03-25
$9.96M
derived: sum of 4 quarters · filed 2026-03-25
2023-12-31$2.69M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
$5.05M
derived: sum of 2 quarters · filed 2026-03-25
$7.57M
derived: sum of 3 quarters · filed 2026-03-25
$9.62M
10-K · filed 2026-03-25
2023-09-30$2.37M
10-Q · filed 2024-11-08
$4.88M
derived: sum of 2 quarters · filed 2024-11-08
$6.93M
10-Q · filed 2024-11-08
$9.66M
derived: sum of 4 quarters · filed 2025-03-21
2023-06-30$2.51M
10-Q · filed 2024-08-13
$4.57M
10-Q · filed 2024-08-13
$7.29M
derived: sum of 3 quarters · filed 2025-03-21
$9.39M
derived: sum of 4 quarters · filed 2025-03-21
2023-03-31$2.05M
10-Q · filed 2024-05-10
$4.78M
derived: sum of 2 quarters · filed 2025-03-21
$6.88M
derived: sum of 3 quarters · filed 2025-03-21
$8.98M
derived: sum of 4 quarters · filed 2025-03-21
2022-12-31$2.73M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21
$4.83M
derived: sum of 2 quarters · filed 2025-03-21
$6.93M
derived: sum of 3 quarters · filed 2025-03-21
$8.94M
10-K · filed 2025-03-21
2022-09-30$2.10M
10-Q · filed 2023-11-13
$4.20M
derived: sum of 2 quarters · filed 2023-11-13
$6.21M
10-Q · filed 2023-11-13
$7.94M
derived: sum of 4 quarters · filed 2024-03-22
2022-06-30$2.10M
10-Q · filed 2023-08-10
$4.11M
10-Q · filed 2023-08-10
$5.83M
derived: sum of 3 quarters · filed 2024-03-22
$7.24M
derived: sum of 4 quarters · filed 2024-03-22
2022-03-31$2.01M
10-Q · filed 2023-05-11
$3.73M
derived: sum of 2 quarters · filed 2024-03-22
$5.14M
derived: sum of 3 quarters · filed 2024-03-22
$7.07M
derived: sum of 4 quarters · filed 2024-03-22
2021-12-31$1.73M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22
$3.13M
derived: sum of 2 quarters · filed 2024-03-22
$5.06M
derived: sum of 3 quarters · filed 2024-03-22
$6.74M
10-K · filed 2024-03-22
2021-09-30$1.41M
10-Q · filed 2022-11-10
$3.34M
derived: sum of 2 quarters · filed 2022-11-10
$5.02M
10-Q · filed 2022-11-10
$6.18M
derived: sum of 4 quarters · filed 2023-03-23
2021-06-30$1.93M
10-Q · filed 2022-08-11
$3.61M
10-Q · filed 2022-08-11
$4.77M
derived: sum of 3 quarters · filed 2023-03-23
$5.97M
derived: sum of 4 quarters · filed 2023-03-23
2021-03-31$1.68M
10-Q · filed 2022-05-11
$2.84M
derived: sum of 2 quarters · filed 2023-03-23
$4.04M
derived: sum of 3 quarters · filed 2023-03-23
$5.02M
derived: sum of 4 quarters · filed 2023-03-23
2020-12-31$1.16M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23
$2.36M
derived: sum of 2 quarters · filed 2023-03-23
$3.34M
derived: sum of 3 quarters · filed 2023-03-23
$4.25M
10-K · filed 2023-03-23
2020-09-30$1.20M
10-Q · filed 2021-11-12
$2.18M
derived: sum of 2 quarters · filed 2021-11-12
$3.09M
10-Q · filed 2021-11-12
$4.01M
derived: sum of 4 quarters · filed 2022-03-23
2020-06-30$979.00K
10-Q · filed 2021-08-12
$1.89M
10-Q · filed 2021-08-12
$2.81M
derived: sum of 3 quarters · filed 2022-03-23
$3.33M
derived: sum of 4 quarters · filed 2022-03-23
2020-03-31$912.00K
10-Q · filed 2021-05-14
$1.83M
derived: sum of 2 quarters · filed 2022-03-23
$2.35M
derived: sum of 3 quarters · filed 2022-03-23
$3.40M
derived: sum of 4 quarters · filed 2022-03-23
2019-12-31$921.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23
$1.44M
derived: sum of 2 quarters · filed 2022-03-23
$2.49M
derived: sum of 3 quarters · filed 2022-03-23
$4.15M
10-K · filed 2022-03-23
2019-09-30$516.00K
10-Q · filed 2020-11-12
$1.57M
derived: sum of 2 quarters · filed 2020-11-12
$3.23M
10-Q · filed 2020-11-12
$4.21M
derived: sum of 4 quarters · filed 2021-03-25
2019-06-30$1.05M
10-Q · filed 2020-08-13
$2.71M
10-Q · filed 2020-08-13
$3.69M
derived: sum of 3 quarters · filed 2021-03-25
$4.74M
derived: sum of 4 quarters · filed 2021-03-25
2019-03-31$1.66M
10-Q · filed 2020-05-15
$2.64M
derived: sum of 2 quarters · filed 2021-03-25
$3.68M
derived: sum of 3 quarters · filed 2021-03-25
2018-12-31$977.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25
$2.02M
derived: sum of 2 quarters · filed 2021-03-25
$4.34M
10-K · filed 2021-03-25
2018-09-30$1.04M
10-Q · filed 2019-12-18
$3.36M
10-Q · filed 2019-12-18
2017-12-31$5.79M
10-K · filed 2020-03-30

Similar stocks

Stock NameCountryMarket CapPE Ratio
Xtant Medical Holdings, Inc. (XTNT)United States$0.053B
Spectral AI, Inc. (MDAI)United States$0.052B
Sensus Healthcare, Inc. (SRTS)United States$0.048B-3.24
DarioHealth Corp. (DRIO)$0.066B-1.39
CVRx, Inc. (CVRX)United States$0.067B-2.62
NEPHROS INC (NEPH)United States$0.046B23.02
SANUWAVE Health, Inc. (SNWV)United States$0.041B5.47
FRACTYL HEALTH, INC. (GUTS)United States$0.075B-1.18
RenovoRx, Inc. (RNXT)United States$0.076B-3.62
InspireMD, Inc. (NSPR)$0.033B